Trial Profile
Cohort Study of Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease Initiating Olodaterol or Other Long-acting beta2-agonists
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 21 Aug 2020 Status changed from active, no longer recruiting to completed.
- 25 Nov 2019 Planned number of patients changed from 1 to 150000.
- 26 Jun 2018 Planned End Date changed from 31 Mar 2020 to 31 Jul 2020.